The brochure, developed by North Carolina Genomic Evaluation by Next-generation Exome Sequencing (NCGENES), includes information about whole exome sequencing (WES), the three types of incidental information revealed by WES (medically actionable, not medically actionable, and no known medical value), and how NCGENES will allocate participants into groups to study two return of results decision interventions.

The brochure, developed by North Carolina Genomic Evaluation by Next-generation Exome Sequencing (NCGENES), describes Whole Exome Sequencing (WES) and six types of non-medically actionable incidental information that might be returned to NCGENES participants. This information is designed to help patients make an informed decision about whether or not to learn non-medically actionable incidental information that could be uncovered during whole exome sequencing.

The study brochure for the North Carolina Genomic Evaluation by Next-generation Exome Sequencing (NCGENES) study includes information on what whole exome sequencing is, why the study is being conducted, who can join, the health problems studied, how many participants can join, and what participants will be asked to do.

These patient vignettes, based on the experiences of real participants in the Michigan Oncology Sequencing Center (MI-ONCOSEQ) DNA sequencing study, help adults understand what to expect should they choose to participate in the study and receive or choose not to receive certain study results.

This document provides answers to frequently asked questions for participants in Personalized Oncology Through High-throughput Sequencing: Michigan Oncology Sequencing Center (MI-ONCOSEQ) Study.

This recruitment brochure for the CanSeq Study provides details about the study rationale and information designed to help adults weigh the risks and benefits associated with participation.

This recruitment brochure for the ClinSeq Study provides details about the study rationale, the risks and benefits associated with participation, and the enrollment procedure.

This fact sheet describes the rights protected by the Genetic Information Nondiscrimination Act of 2008 in an easy to read format.

The Research Participant's Authorization to Disclose/Release Genetic Information Form for the NEXT (New EXome Technology in Medicine) Medicine Study authorizes the principal investigator of the study to disclose the participant's genetic research results to a specified person in the case of participant death or incapacitation.

This consent form for the NEXT Medicine Study is designed for individuals with endometrial/uterine cancer or a close family member with this type of cancer. It contains information about the study and the researchers involved, the purpose of the study, what is involved in participating, potential risks and benefits of participating, financial questions and answers related to the study, and who to contact with questions.